A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

NCT03666715 · clinicaltrials.gov ↗

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Oral Antipsychotics (OAPs)
DRUG: Paliperidone Palmitate 1-Month Formulation (PP1M)

Sponsor

Janssen-Cilag Farmaceutica Ltda.